INDV

Indivior Pharmaceuticals Inc · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:32 UTC

Last close

36.28USD

Market data, 2026-11-02

Except where said otherwise: 10-K for 2025, filed 2026-02-26

21.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
396.9%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
The filing itself
16.9%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-7.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-10-29
The filing itself
n/aDividend yield
The stored value is a zero that stands for missing data rather than a measurement, so we will not place it.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
- Computed from the filing for 2016

Safety is the furthest below its sector's middle: 0.44 against 0.53 on the market's range.

What it pays out: n/aThe stored value is a zero that stands for missing data rather than a measurement, so we will not place it.

Then and now

lens 3 of 9

Five filed facts, 2016 against 2025.
Fact	2016	2025	Change
Sales	968,885,463	1,239,000,000	+27.9%
Profit	32,051,976	210,000,000	+555%
Free cash flow	372,000,000	-93,000,000	-125%
Debt	534,999,773	351,000,000	-34.4%
Shares in issue	n/a	128,000,000	n/a

The same five facts for 2016 and 2025, each read from the year's own filing.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2016

Sales, 2016968,885,463
Source
computed
Statement
income
Fiscal year
2016
Reported in
USD
Sales, 20251,239,000,00010-K for 2025, filed 2026-02-26
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Profit, 201632,051,976
Source
computed
Statement
income
Fiscal year
2016
Reported in
USD
Profit, 2025210,000,00010-K for 2025, filed 2026-02-26
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Free cash flow, 2016372,000,000
Source
computed
Statement
income
Fiscal year
2016
Reported in
USD
Free cash flow, 2025-93,000,00010-K for 2025, filed 2026-02-26
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Debt, 2016534,999,773
Source
computed
Statement
income
Fiscal year
2016
Reported in
USD
Debt, 2025351,000,00010-K for 2025, filed 2026-02-26
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself
Shares in issue, 2016n/a
Not held.
Source
computed
Statement
income
Fiscal year
2016
Reported in
USD
Shares in issue, 2025128,000,00010-K for 2025, filed 2026-02-26
Source
filed
Statement
income
Fiscal year
2025
Accession
0001628280-26-012237
Reported in
USD
The filing itself